Option chain shows key data for Petros Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Petros Pharma.

Petros Pharma (NASDAQ:PTPI) Stock, Option Chain

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

Crude Oil and Petroleum Trade in the Crosshairs

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

PRFX

PTPI

SEPN

SMCI

Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings

Medtronic, Fluor And 3 Stocks To Watch Heading Into Tuesday

BPTH

HCTI

US Stocks Mixed; NY State Business Activity Rises In February

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Movers

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

QNTM

SGMO

SLXN

VRAX

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 46 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 39%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $378,149, and 38 are calls, for a total amount of $5,040,761.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $750.0 and $1080.0 for Eli Lilly, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $750.0 to $1080.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740079838_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$70.15</td>
<td>$67.5</td>
<td>$69.0</td>
<td>$1000.00</td>
<td>$2.7M</td>
<td align="right">300</td>
<td align="right">1</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$70.0</td>
<td>$65.9</td>
<td>$69.0</td>
<td>$1000.00</td>
<td>$690.0K</td>
<td align="right">300</td>
<td align="right">401</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$135.8</td>
<td>$134.3</td>
<td>$135.8</td>
<td>$840.00</td>
<td>$162.9K</td>
<td align="right">142</td>
<td align="right">0</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$12.0</td>
<td>$11.75</td>
<td>$12.0</td>
<td>$870.00</td>
<td>$97.2K</td>
<td align="right">98</td>
<td align="right">183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$37.7</td>
<td>$36.85</td>
<td>$37.7</td>
<td>$880.00</td>
<td>$79.1K</td>
<td align="right">208</td>
<td align="right">28</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>With a volume of 1,600,917, the price of LLY is up 0.69% at $873.03. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 70 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1066.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $970. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Eli Lilly, targeting a price of $1038. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on Eli Lilly with a target price of $1190. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Eli Lilly's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bullish approach towards Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in EOSE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Eos Energy Enterprises. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable options, 2 are puts, totaling $65,400, and 8 are calls, amounting to $394,003.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1.0 to $7.5 for Eos Energy Enterprises over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Eos Energy Enterprises's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Eos Energy Enterprises's substantial trades, within a strike price spectrum from $1.0 to $7.5 over the preceding 30 days.
<h3>Eos Energy Enterprises Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740079833_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$0.83</td>
<td>$0.82</td>
<td>$0.82</td>
<td>$5.00</td>
<td>$82.0K</td>
<td>17.3K</td>
<td>3.1K</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.55</td>
<td>$1.39</td>
<td>$1.43</td>
<td>$5.00</td>
<td>$71.5K</td>
<td>45.2K</td>
<td>623</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.85</td>
<td>$3.7</td>
<td>$3.82</td>
<td>$1.00</td>
<td>$62.6K</td>
<td>14.2K</td>
<td>394</td>
</tr>
<tr>
<td>EOSE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.8</td>
<td>$3.4</td>
<td>$3.75</td>
<td>$1.00</td>
<td>$61.5K</td>
<td>14.2K</td>
<td>194</td>
</tr>
<tr>
<td>EOSE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$0.4</td>
<td>$0.33</td>
<td>$0.36</td>
<td>$3.50</td>
<td>$36.0K</td>
<td>2.4K</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Eos Energy Enterprises</h3>
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial &amp; industrial (C&amp;I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
Following our analysis of the options activities associated with Eos Energy Enterprises, we pivot to a closer look at the company's own performance.
<h3>Eos Energy Enterprises's Current Market Status</h3>
<ul>
<li>Trading volume stands at 6,363,001, with EOSE's price down by -4.98%, positioned at $4.58.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 12 days.</li>
</ul>
<h3>What The Experts Say On Eos Energy Enterprises</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $5.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Roth MKM downgraded its action to Neutral with a price target of $5. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eos Energy Enterprises, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

EOSE

Behind the Scenes of Eos Energy Enterprises's Latest Options Trends

Investors with a lot of money to spend have taken a bullish stance on SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SAP, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 13 uncommon options trades for SAP.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 38%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $395,090, and 7 are calls, for a total amount of $618,743.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $170.0 and $310.0 for SAP, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for SAP options trades today is 101.5 with a total volume of 767.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for SAP's big money trades within a strike price range of $170.0 to $310.0 over the last 30 days.
<h3>SAP Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740079827_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$11.3</td>
<td>$11.2</td>
<td>$11.3</td>
<td>$290.00</td>
<td>$212.4K</td>
<td align="right">0</td>
<td align="right">253</td>
</tr>
<tr>
<td>SAP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$9.5</td>
<td>$9.2</td>
<td>$9.2</td>
<td>$300.00</td>
<td>$168.2K</td>
<td align="right">0</td>
<td align="right">16</td>
</tr>
<tr>
<td>SAP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.0</td>
<td>$12.4</td>
<td>$12.6</td>
<td>$280.00</td>
<td>$126.0K</td>
<td align="right">288</td>
<td align="right">90</td>
</tr>
<tr>
<td>SAP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$120.6</td>
<td>$117.1</td>
<td>$119.2</td>
<td>$170.00</td>
<td>$95.3K</td>
<td align="right">9</td>
<td align="right">0</td>
</tr>
<tr>
<td>SAP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.7</td>
<td>$17.5</td>
<td>$17.5</td>
<td>$290.00</td>
<td>$82.2K</td>
<td align="right">109</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About SAP</h3>
Founded in Germany in 1972 by former IBM employees, SAP is the world's largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP's portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.
Having examined the options trading patterns of SAP, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is SAP Standing Right Now?</h3>
<ul>
<li>With a volume of 426,112, the price of SAP is up 0.2% at $289.04. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 61 days.</li>
</ul>
<h3>What The Experts Say On SAP</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $248.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for SAP, targeting a price of $286. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $38. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for SAP, targeting a price of $283. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for SAP, targeting a price of $307. 
&#x2A; Maintaining their stance, an analyst from JMP Securities continues to hold a Market Outperform rating for SAP, targeting a price of $330. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for SAP with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

SAP's Options Frenzy: What You Need to Know

WIIM

IMUX

Immunic shares are trading higher after the company announced its ORAL IMU-856 demonstrated a dose-dependent increase of GLP-1 in celiac disease patients.

The Board of Directors of The Coca-Cola Company today approved the company's 63rd consecutive annual dividend increase, raising the quarterly dividend approximately 5.2% from 48.5 cents to 51 cents per common share.
The quarterly dividend is equivalent to an annual dividend of $2.04 per share, up from $1.94 per share in 2024. The first quarter dividend is payable April 1 to shareowners of record as of March 14.
The company returned $8.4 billion in dividends to shareowners in 2024, bringing the total amount of dividends paid to shareowners since Jan. 1, 2010, to $93.1 billion.

Dividends

The Coca-Cola Company Increases Quarterly Dividend From $0.485 To $0.51 Per Share

Ferrari N.V. (NYSE/EXM: RACE) (the "Company") announced today that its Board of Directors intends to recommend to the Company's shareholders a dividend distribution to the holders of common shares of Euro 2.986 per common share, with an increase of approximately 22% compared to the prior year and corresponding to a total distribution of approximately Euro 534 million.

RACE

Ferrari Intends To Recommend ~22% Increase In Dividend To €2.986/Share, Totaling ~€534 Million

TrueBlue shares are trading lower. The company reported Q4 financial results.

Scotiabank analyst Mario Saric maintains Riocan REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REI#TSX">REI</a>) with a Sector Perform and raises the price target from C$20.75 to C$21.5.

Price Target

Analyst Ratings

TSX:REI

TSX:REI/UN

Scotiabank Maintains Sector Perform on Riocan REIT, Raises Price Target to C$21.5

Financial technology company Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) could highlight its growth across several sectors along with its place in the cryptocurrency ecosystem when the company reports fourth-quarter financial results Thursday <a href="https://www.benzinga.com/quote/XYZ/earnings">after market close.</a>
Earnings Estimates: Analysts expect Block to report fourth-quarter revenue of $6.29 billion, up from $5.77 billion in last year's fourth quarter.
The company missed analyst revenue estimates in the last two straight quarters, but has beaten estimates in eight of the last 10 quarters.
Analysts expect the company to report fourth-quarter earnings per share of 87 cents, up from 45 cents per share in last year's fourth quarter. The company has beaten analyst estimates for earnings per share in three straight quarters and eight of the last 10 quarters overall.
What Analysts Are Saying: The resurgence of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) could be a positive narrative for Block, RBC Capital analyst Daniel Perlin said in a new investor note.
The analyst has an Outperform rating and $110 price target ahead of fourth-quarter earnings.
"Given the resurgence in investor interest in bitcoin and the expectation for regulatory clarity, we believe that XYZ's 4Q24 results will include increased commentary regarding it leaning more into its bitcoin strategy," Perlin said.
The analyst said this could include comments on the company's crypto mining and wallets efforts along with commerce use cases.
"We believe the increased commentary combined with a positive narrative will drive investor interest, who will begin the bake more than just its core Cash App and Square businesses into the stock's valuation."
The analyst highlighted Block's 8,363 reported held bitcoin at the end of the third quarter along with incremental bitcoin purchases that could total around $781 million in holdings at the end of the fourth quarter.
Block's push into bitcoin mining could highlight the company's technological expertise and growth in the cryptocurrency ecosystem, Perlin added.
"The bitcoin narrative has more substance now. While positive for the stock, we don't see bitcoin sales as the reason to buy XYZ. What we do see as a more legitimate reason is the belief that longer-term, Block will leverage its two-sided network and integration with the Lightning Network to be the facilitator of bitcoin's commerce use case."
The analyst said Block will operate in several crypto sectors where there are only a handful of competitors.
The analyst views President Donald Trump's pro-crypto stance as positive for Block. The president has appointed several crypto advocates to notable financial roles in the White House administration.
"We believe that regulatory momentum has no reason to slow, which could lead to a greater level of bitcoin's integration into traditional financial services and commerce."
Bank of America analyst Jason Kupferberg recently named Block as a top Payments pick for 2025. The analyst has a Buy rating and a $115 price target.
Kupferberg said Block has the potential to outperform thanks to a favorable macro backdrop and growth in the company's Square gross payments volume.
The analyst said Block will likely achieve the Rule of 40, or revenue growth and profit margin added together, equaling 40 or more, sooner than anticipated. Kupferberg predicts this could lead to Block being added to the S&amp;P 500.
XYZ Price Action: Block stock is down 1.3% to $82.78 on Thursday versus a 52-week trading range of $55.00 to $99.26. Block stock is up 25% over the last year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43856737/applovin-stock-tumbles-as-short-seller-takes-a-closer-look-at-whats-driving-enormous-gains">AppLovin Stock Tumbles As Short Seller Takes Closer Look At What&#8217;s Driving Enormous Gains</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Tech

$BTC

Block Q4 Earnings Preview: Analyst Says Bitcoin, Trump Factor Could Boost Growth

Scotiabank analyst Orest Wowkodaw maintains Hudbay Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBM#TSX">HBM</a>) with a Sector Outperform and lowers the price target from C$15.5 to C$14.

TSX:HBM

Scotiabank Maintains Sector Outperform on Hudbay Minerals, Lowers Price Target to C$14

Indivior Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) stock plunged following the company&#8217;s fiscal year 2025 guidance that fell short of Street expectations.
Addiction and mental illnesses-focused Indivior reported fourth-quarter sales of $298 million, up 2% year over year, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus</a> of $259.3 million.
The London-based healthcare firm <a target="_blank" href="https://www.indivior.com/resources/dam/id/1487/Indivior%20Q4%202024%20Financial%20Results%20-%20Final.pdf" rel="noreferrer noopener">reported</a> adjusted EPS of 32 cents, down from 43 a year ago, beating the consensus of 21 cents.
In the fourth quarter, adjusted operating profit remained unchanged at $66 million, while adjusted net income declined 33% year-over-year to $41 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41272212/indivior-cuts-2024-outlook-as-competition-and-market-pressures-weigh-on-sublocade-details" rel="noreferrer noopener">Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details</a>
Sales of Sublocade, its newer long-acting treatment for opioid use disorder, increased 10% year over year to $194 million, and U.S. units dispensed were approximately 161,400, up 13%.
Suboxone Film revenue declined in the fourth quarter due to increased generic competitive activity, resulting in an average share of 15.2% versus 18.4% a year ago.
Sales of Perseris, its schizophrenia drug, fell 25% to $9 million. As previously announced, Perseris&#8217; marketing and promotion have been discontinued.
In February, the FDA informed Indivior that, following acceptance of the proposed label for Sublocade, there were no outstanding items for the company to address, but the final review of the label was delayed.
Guidance: Indivior expects 2025 revenue of $955 million to $1.025 billion, versus a consensus of $1.09 billion, representing a 17% decline.
The company expects adjusted EBIT guidance of $185 million to $225 million. Sublocade sales are expected to reach $725 million to $765 million, down 1% year over year.
The guidance anticipates accelerated erosion in Suboxone sales, reflecting an increased generic competitive activity and the potential impact of a fifth buprenorphine/ naloxone sublingual film generic in the U.S. market.
Indivior is cutting over $100 million in costs, of which approximately $50 million will be reinvested in Sublocade and the opioid use disorder-focused pipeline. Over $50 million will help protect adjusted operating profit.
Price Action: INDV stock is down 16.50% to $9.11 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43849900/airbus-q4-earnings-revenue-surges-8-order-intake-value-declines-and-more" target="_blank" rel="noreferrer noopener">Airbus Q4 Earnings: Revenue Surges 8%, Order Intake Value Declines And More</a></li>
</ul>

Biotech

Guidance

Health Care

General

INDV

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Scotiabank analyst Mario Saric maintains CAPREIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAR#TSX">CAR</a>) with a Sector Outperform and lowers the price target from C$52.25 to C$50.

TSX:CAR

TSX:CAR/UN

Scotiabank Maintains Sector Outperform on CAPREIT, Lowers Price Target to C$50

Wall Street analysts rerated Wix.com Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) after the company reported its <a target="_blank" href="https://www.benzinga.com/25/02/43812289/wix-q4-earnings-beats-estimates-raises-2025-outlook-ai-powered-expansion-and-market-share-gains" rel="noreferrer noopener">fourth-quarter results</a> Wednesday amid an exciting earnings season.
Wix.com reported revenue growth of 14%&nbsp;to $460.46 million, missing the&nbsp;analyst estimate of $461.75 million.&nbsp;Adjusted EPS of $1.93 beat the&nbsp;consensus estimate of $1.59.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43846533/alibaba-q3-earnings-revenue-and-eps-beat-eyes-global-e-commerce-profitability-in-fy25-increase-investments-in-ai" rel="noreferrer noopener">Alibaba Q3 Earnings: Revenue And EPS Beat, Eyes Global E-Commerce Profitability In FY25, Increase Investments In AI</a>
Cantor Fitzgerald analyst Deepak Mathivanan maintained Wix.com with an Overweight and raised the <a target="_blank" href="https://www.benzinga.com/quote/WIX/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$260&nbsp;to&nbsp;$270</a>.
Benchmark analyst Mark Zgutowicz reiterated Wix.com with a Buy and raised the price target from&nbsp;$250&nbsp;to&nbsp;$260.
Needham analyst Bernie McTernan maintained Wix.com with a Buy and raised the price target from&nbsp;$235&nbsp;to&nbsp;$250.
RBC Capital analyst Brad Erickson reiterated an Outperform on Wix.com with a price target of $245.
Cantor Fitzgerald: WIX reported fourth-quarter results with revenue in line and free cash flow above Street estimates by 2% (Visible Alpha).
Mathivanan highlighted Studio adoption reflected by its booking growth, momentum in Self Create supported by the rollout of new AI products—the company&#8217;s AI marketing agent has entered the rollout phase—and premium subscriptions led by pricing initiatives and tougher comp from B2B migrations in 2023.
The analyst noted that the company&#8217;s robust product pipeline in 2025 bodes well for top-line growth. Operating margins also have plenty of runway to expand nicely over the next few quarters. Mathivanan projected first-quarter revenue of $472.1 million and adjusted EPS of $1.30.
Benchmark: WIX&#8217;s first-quarter and fiscal 2025 outlook tempered concerns for difficult pricing-related bookings headwind comparisons starting in mid-first-quarter, as the entirety of the respective fiscal 2025 bookings and revenue miss were attributed to FX headwinds.
Notably, WIX&#8217;s fiscal 2025 free cash flow guidance incorporates adjusted opex as a percent of revenue between 47% and 48%, in line with targets set at its fiscal 2023 Investor Day.
Importantly, WIX has not assumed any revenue generation from new products within fiscal 2025 guidance, presenting a potential average revenue per subscription (ARPS) catalyst in the second half across both Self-Creators and Partners.
An underappreciated aspect of the free cash flow margin story remains the sustainable and eventually accretive revenue mix shift toward Partners. Notably, partners&#8217; revenue exhibits lower S&amp;M sensitivities than Self-Creator today, allowing rationalize Partners&#8217; (eventual) accretion potential and emerging automation-based efficiencies.
Regarding WIX&#8217;s top-of-funnel momentum, Zgutowicz is impressed with 75% of the 2M Studio account net adds since launch being net new Partner clients to WIX. Zgutowicz anticipated potential top-of-funnel Partner (Agency) deceleration, given difficult comparisons.
However, the analyst expects Studio to drive accelerative ARPS growth in the second half as Bookings materialize into revenue. Zgutowicz anticipates its new Partner subscribers will deliberately shift portions of workflow to Studio, providing a sustainable ARPS benefit over the medium-to-long term, with pricing power and product innovation at its disposal. Zgutowicz projected first-quarter revenue of $472 million.
Needham: WIX continues to be one of the best product-driven growth stories in McTernan&#8217;s coverage. However, the company&#8217;s reported fiscal 2025 growth is being impacted by FX and compared against a price increase from the prior year. WIX studio is driving many new developers/agencies to the platform, which should be of lasting benefit. 
On Self Creator, WIX is launching new products this year, which could re-accelerate revenue to double-digits, representing an upside to the analyst&#8217;s estimates. McTernan projected first-quarter revenue of $471 million and adjusted EPS of $1.73.
RBC Capital: WIX&#8217;s fourth-quarter print was somewhat mixed, with the main intrigue being the fiscal bookings guide below Street (in-line FX neutral), where expected second-half bookings acceleration implies the year will be more back-end weighted than Street forecasts.
Erickson rerated despite the stock&#8217;s firm run on further new product cycle optimism and rising potential to become a more fully-formed compounder/capital return story. Erickson projected first-quarter revenue of $471.2 million.
Price Action: WIX stock traded lower by 4.82% at $206.54 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43853508/grab-q4-on-demand-incentives-grow-due-to-competition-issues-cautious-fy25-outlook-despite-strong-gmv-and-user-growth" target="_blank" rel="noreferrer noopener">Grab Q4 On-Demand Incentives Grow Due To Competition, Issues Cautious FY25 Outlook Despite Strong GMV And User Growth</a></li>
</ul>
Image via Shutterstock.

Reiteration

Wix Is One Of The Best Product-Driven Growth Stories, Analyst Says

Scotiabank analyst Meny Grauman maintains Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Sector Perform and lowers the price target from C$83 to C$82.

TSX:TD

Scotiabank Maintains Sector Perform on Toronto-Dominion Bank, Lowers Price Target to C$82

Barstool Sports founder Dave Portnoy, known for his outspoken commentary, is calling for a sweeping &#8220;clean up&#8221; of the cryptocurrency space as the Stool Prisondente (CRYPTO: JAILSTOOL), is <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43643442/dave-portnoy-holds-millions-in-bitcoin-and-xrp-but-heres-why-he-concluded-his-heart-is-too">plummeting in value.</a>
In a post on X Thursday, Portnoy <a href="https://x.com/stoolpresidente/status/1892594369733206090">wrote</a>, "So manny scammers and liars out there. Let's clean this space up! Take out the trash. Together we can win. This is when it pays to be the cleanest man in crypto."
His remarks come just days after Jailstool's price dropped from 21 cents to 1 cent, wiping out millions of <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43636904/anthony-scaramucci-warns-meme-coins-create-market-contagion-fuel-bitcoin-skepticism">dollars of investor funds</a>, according to data from Dexscreener.
&#8220;Can we arrest the crybabies who are told not to risk more than they can lose and that Memecoins are a risk and then cry foul too?&#8221; he further said, in an apparent dig at retail investors, who lost funds investing in the meme coin.
While Portnoy insists he remains committed to the project, his role in its promotion has divided the crypto community.
<h3 class="wp-block-heading">Portnoy's Role In The Jailstool Crash</h3>
Portnoy claimed he had initially invested hundreds of thousands of dollars into Jailstool and publicly declared his support for the token. 
Even as prices tumbled, he insisted he was putting in more of his own money to prevent losses for other investors.
"The fact I'm still putting my own money into #Jailstool cause I don't want people losing money shows that my heart is too big for this stupid space," Portnoy posted on X.
Despite his claims of loyalty to the project, Jailstool's sharp decline has fueled accusations that his marketing efforts failed, leaving retail investors at a disadvantage.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43857831/sec-scales-back-crypto-enforcement-expands-focus-to-cyber-fraud">SEC Scales Back Crypto Enforcement, Expands Focus To Cyber Fraud</a>
<h3 class="wp-block-heading">Market Reaction And Crypto Community Divisions</h3>
The crypto community remains split on Portnoy's role. 
Some believe he is genuinely backing the coin, while others argue his involvement has caused more harm than good.
Crypto analyst Stats pointed out that Jailstool has nearly returned to its pre-promotion price, raising concerns about the effectiveness of Portnoy's influence.
"His marketing plays didn't work out. People lost real money (which is 100% their own fault). But I think his credibility in this space is pretty ruined," Stats wrote.
Others, such as Kaleo, speculated that Portnoy may keep investing in Jailstool to salvage its price. They suggested that if he faces further losses, he may turn against meme coins altogether.
<h3 class="wp-block-heading">What's Next For Portnoy And Jailstool?</h3>
While Portnoy maintains that he could have cashed out for millions but chose not to, questions remain about his long-term involvement in crypto. 
His call to "clean up the space" has been met with skepticism, as many point to Jailstool's crash as an example of why stronger oversight is needed.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43855374/studying-bitcoin-will-strengthen-us-czech-central-bank-governor-says">Studying Bitcoin Will Strengthen Us, Czech Central Bank Governor Says</a></li>
</ul>
Image: Shutterstock

Dave Portnoy Calls For A 'Crypto Cleanup,' But Here's What Could Make That Tricky

Scotiabank analyst Meny Grauman maintains Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) with a Sector Outperform and lowers the price target from C$197 to C$191.

TSX:RY

Scotiabank Maintains Sector Outperform on Royal Bank of Canada, Lowers Price Target to C$191

Scotiabank analyst Meny Grauman maintains National Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NA#TSX">NA</a>) with a Sector Perform and lowers the price target from C$154 to C$125.

TSX:NA

Scotiabank Maintains Sector Perform on National Bank of Canada, Lowers Price Target to C$125

EYPT

Traders Circulate Unconfirmed Report On Social Media That Eyepoint Pharmaceuticals Received National Medical Products Administration Approval Of Dexycu In China To Treat Post-Operative Inflammation Following Ocular Surgery

Scotiabank analyst Meny Grauman maintains Laurentian Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LB#TSX">LB</a>) with a Sector Perform and lowers the price target from C$33 to C$28.

TSX:LB

Scotiabank Maintains Sector Perform on Laurentian Bank of Canada, Lowers Price Target to C$28

Schlumberger Option Alert: Feb 28 $44 Calls Sweep (55) near the Ask: 2075 @ $0.29 vs 741 OI; Earnings 4/21 Before Open [est] Ref=$42.865

Press Releases

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Events

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

Petros Pharmaceuticals Featured in "New Era of Healthcare, AI, Data and Consumer Empowerment"

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants

Comments

Petros Pharma

Petros Pharma (PTPI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga